<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>7(1)</volume><submitter>Xie C</submitter><pubmed_abstract>Glypican-3 (GPC3) is a promising new marker for hepatocellular carcinoma, but the reported values for serum GPC3 differ markedly between currently available kits. Here we isolated Affimer non-antibody binding proteins against GPC3 by phage display and developed a new sandwich chemiluminescence immunoassay (CLIA) combining an Affimer with a monoclonal antibody (Affimer-MAb CLIA). The proposed CLIA assay demonstrated a wide linear range  0.03-600 ng/mL) with a good linear correlation coefficient (0.9999), a high detection limitation (0.03 ng/mL) and specificity (0-0.002%) for detection of GPC3. The accuracy, hook effect and stability were demonstrated to be satisfactory. The mean level of GPC3 in serum was higher (>8.5 fold, P &lt; 0.001) in hepatocellular carcinoma patients compared to healthy</pubmed_abstract><journal>Scientific reports</journal><pagination>9608</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC5575301</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Development of an Affimer-antibody combined immunological diagnosis kit for glypican-3.</pubmed_title><pmcid>PMC5575301</pmcid><pubmed_authors>Tomlinson DC</pubmed_authors><pubmed_authors>Tiede C</pubmed_authors><pubmed_authors>Li Z</pubmed_authors><pubmed_authors>Wang C</pubmed_authors><pubmed_authors>Zhang X</pubmed_authors><pubmed_authors>Xu X</pubmed_authors><pubmed_authors>Xu W</pubmed_authors><pubmed_authors>Xie C</pubmed_authors><pubmed_authors>McPherson MJ</pubmed_authors></additional><is_claimable>false</is_claimable><name>Development of an Affimer-antibody combined immunological diagnosis kit for glypican-3.</name><description>Glypican-3 (GPC3) is a promising new marker for hepatocellular carcinoma, but the reported values for serum GPC3 differ markedly between currently available kits. Here we isolated Affimer non-antibody binding proteins against GPC3 by phage display and developed a new sandwich chemiluminescence immunoassay (CLIA) combining an Affimer with a monoclonal antibody (Affimer-MAb CLIA). The proposed CLIA assay demonstrated a wide linear range  0.03-600 ng/mL) with a good linear correlation coefficient (0.9999), a high detection limitation (0.03 ng/mL) and specificity (0-0.002%) for detection of GPC3. The accuracy, hook effect and stability were demonstrated to be satisfactory. The mean level of GPC3 in serum was higher (>8.5 fold, P &lt; 0.001) in hepatocellular carcinoma patients compared to healthy</description><dates><release>2017-01-01T00:00:00Z</release><publication>2017 Aug</publication><modification>2025-04-04T03:06:18.324Z</modification><creation>2019-03-27T02:54:48Z</creation></dates><accession>S-EPMC5575301</accession><cross_references><pubmed>28852111</pubmed><doi>10.1038/s41598-017-10083-w</doi></cross_references></HashMap>